Keyword

LCL161

Description: An orally administered small-molecule drug that mimics SMAC and antagonizes inhibitor-of-apoptosis proteins in cancer research and treatment.
OpenAlex ID: keywords/lcl161
2015 · Simone Fulda · Clinical Cancer Research · 221
2016 · Marta Chesi, Noweeda N Mirza, et al. · Nature Medicine · 181
2018 · Nobumichi Ohoka, Yoko Morita, et al. · Journal of Biological Chemistry · 111
2010 · E Weisberg, A Ray, et al. · Leukemia · 104
2011 · Peter J. Houghton, Min H. Kang, et al. · Pediatric Blood & Cancer · 96
2012 · Kuen-Feng Chen, Jing-Ping Lin, et al. · Biochemical Pharmacology · 70
2020 · Yung-Chieh Chang, Chun Hei Antonio Cheung · Applied Sciences · 53
2020 · Boxiang Zhang, Chengcheng Yang, et al. · Journal of Experimental & Clinical Cancer Research · 49
2014 · Aiping Tian, George S. Wilson, et al. · Cancer Letters · 49
2021 · Naveen Pemmaraju, Bing Z. Carter, et al. · Blood Advances · 46
2023 · Parima Udompholkul, Ana Garza-Granados, et al. · Journal of Medicinal Chemistry · 40
2019 · Tanmay M. Shekhar, Ingrid J. G. Burvenich, et al. · BMC Cancer · 38
2018 · Shawn T. Beug, Stephanie J. Pichette, et al. · Molecular Therapy — Oncolytics · 36
2020 · Yung-Chieh Chang, Sree Karani Kondapuram, et al. · Toxicology and Applied Pharmacology · 35
Works count: 151
Citation count: 2,811
Year
Topic
Type